title: [Gout - regardless of therapeutic options a "forgotten" disease].
abstract: Compared to other chronic inflammatory diseases, gout appears to based on a rather "simple" pathophysiology and therefore the amount of teaching time in medical school and during internship is rather limited. On the other hand, several problems in short- and long-term management still need to be solved - combined with the problem of an increased incidence in elderly people. However, there is significant advance in the knowledge of its pathophysiology including the fact that gout is more than a pure "crystal arthopathy" but rather within the spectrum of chronic inflammatory immunologic diseases. This includes cytokines such as interleukin-1 and intracellular signaling via the inflammasome. For treatment, the novel and effective xanthine oxidase inhibitor febuxostat has been added to the therapeutic armamentarium. Guidelines of EULAR and BSR support the physician in the long-term management of the numerous gout patients.
authors.affiliation: Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig Universität Gießen, Kerckhoff-Klinik Bad Nauheim. U.Mueller-Ladner@kerckhoff-klinik.de
authors.forename: U
authors.initials: U
authors.lastname: Müller-Ladner
authors.forename: I
authors.initials: I
authors.lastname: Panzner
authors.forename: J
authors.initials: J
authors.lastname: Kriegsmann
authors.forename: U
authors.initials: U
authors.lastname: Lange
authors.forename: A-K
authors.initials: AK
authors.lastname: Tausche
mesh_terms: D000493:Allopurinol / Q000009:adverse effects / Q000627:therapeutic use; D015210:Arthritis, Gouty / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D001553:Benzbromarone / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood; D005060:Europe; D000069465:Febuxostat; D006073:Gout / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D006074:Gout Suppressants / Q000009:adverse effects / Q000627:therapeutic use; D019983:Guideline Adherence; D006801:Humans; D058847:Inflammasomes / Q000502:physiology; D007375:Interleukin-1 / Q000097:blood; D008134:Long-Term Care; D011339:Probenecid / Q000009:adverse effects / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood
chemical_list: D016207:Cytokines; D006074:Gout Suppressants; D058847:Inflammasomes; D007375:Interleukin-1; D013844:Thiazoles; D000069465:Febuxostat; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol; D011339:Probenecid